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Abstract
Background: Fanconi anemia (FA) is a rare disorder characterized by congenital
malformations, progressive bone marrow failure, and predisposition to cancer.
Patients harboring X-linked FANCB pathogenic variants usually present with sev-
ere congenital malformations resembling VACTERL syndrome with hydro-
cephalus.
Methods: We employed the diepoxybutane (DEB) test for FA diagnosis,
arrayCGH for detection of duplication, targeted capture and next-gen sequencing
for defining the duplication breakpoint, PacBio sequencing of full-length FANCB
aberrant transcript, FANCD2 ubiquitination and foci formation assays for the
evaluation of FANCB protein function by viral transduction of FANCB-null cells
with lentiviral FANCB WT and mutant expression constructs, and droplet digital
PCR for quantitation of the duplication in the genomic DNA and cDNA.
Results: We describe here an FA-B patient with a mild phenotype. The DEB
diagnostic test for FA revealed somatic mosaicism. We identified a 9154 bp intra-
genic duplication in FANCB, covering the first coding exon 3 and the flanking
regions. A four bp homology (GTAG) present at both ends of the breakpoint is
consistent with microhomology-mediated duplication mechanism. The duplicated
allele gives rise to an aberrant transcript containing exon 3 duplication, predicted
to introduce a stop codon in FANCB protein (p.A319*). Duplication levels in the
peripheral blood DNA declined from 93% to 7.9% in the span of eleven years.
Moreover, the patient fibroblasts have shown 8% of wild-type (WT) allele and his
carrier mother showed higher than expected levels of WT allele (79% vs. 50%) in
peripheral blood, suggesting that the duplication was highly unstable.
*Both authors contributed equally to the manuscript.
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Conclusion: Unlike sequence point variants, intragenic duplications are difficult
to precisely define, accurately quantify, and may be very unstable, challenging
the proper diagnosis. The reversion of genomic duplication to the WT allele
results in somatic mosaicism and may explain the relatively milder phenotype dis-
played by the FA-B patient described here.
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1 | INTRODUCTION
Fanconi anemia (FA) is a DNA repair deficiency syn-
drome, and is characterized by developmental abnormali-
ties, bone marrow failure, and predisposition to cancer,
including myelodysplastic syndrome (MDS), acute myeloid
leukemia (AML) and solid tumors, especially squamous
cell carcinoma of the head and neck (Kottemann & Smo-
gorzewska, 2013; Mamrak, Shimamura, & Howlett, 2017;
Mehta & Tolar, 2017). Apart from X-linked FANCB, and
dominant negative variants in RAD51/FANCR, FA is an
autosomal recessive disease, caused by the inheritance of
biallelic mutations in any of the 20 other FA genes:
FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE,
FANCF, FANCG, FANCI, FANCJ/BRIP1, FANCL,
FANCM, FANCN/PALB2, FANCO/RAD51C, FANCP/
SLX4, FANCQ/XPF, FANCS/BRCA1, FANCT/UBE2T,
FANCU/XRCC2, FANCV/REV7, FANCW/RFWD3 (Knies
et al., 2017; Mamrak et al., 2017; Wang & Smogorzewska,
2015). FA is both genetically and phenotypically a hetero-
geneous disorder. The underlying problem is inability of
FA cells to repair DNA interstrand crosslinks (ICLs).
The congenital abnormalities in an FA patient may
affect multiple organ systems and include growth (short
stature), skin pigmentation, thumb and radial bone, uro-
genital, eye, ear and hearing, gastrointestinal, and central
nervous system (CNS) anomalies (Auerbach, 2009). The
phenotypic expression of these abnormalities is highly vari-
able, and is displayed by about two-thirds of FA patients.
However, the malformations are usually severe in FA-B
patients. In fact, presentations of X-linked VACTERL with
hydrocephalus syndrome resulting in vertebral anomalies
(V), anal atresia (A), cardiac anomalies (C), tracheoe-
sophageal fistula (T), esophageal atresia (E), renal
structural anomalies (R) limb anomalies (L), and hydro-
cephalus (H) overlap with those displayed by FA-B patients
(Alter & Rosenberg, 2013; Holden et al., 2006; McCauley
et al., 2011; Mikat et al., 2016; Umana, Magoulas, Bi, &
Bacino, 2011; Winberg et al., 2014). However, a positive
FA diagnostic test, with increased chromosomal breakage in
patient cells upon exposure to DNA crosslinking agents
diepoxybutane (DEB) or mitomycin C (MMC), distinguishes
FA-B patients from the VACTERL patients.
Somatic (or revertant) mosaicism has been observed in
nearly 25% of FA patients (Auerbach, 2009). It manifests
itself by the appearance of a population of blood cells that
lost the crosslink sensitivity and now appear WT. Mosai-
cism can be caused by the reversion of an inherited muta-
tion or the introduction of a de novo variant with a
consequence of reducing or eliminating the deleterious nat-
ure of the inherited variant (Gregory et al., 2001; Gross
et al., 2002; Hamanoue et al., 2006; Lo Ten Foe et al.,
1997; Mankad et al., 2006; Waisfisz et al., 1999).
We report here an FA patient who harbors an intragenic
duplication in FANCB (OMIM: 300515) and displays a
mild disease phenotype. We suggest that this unusual phe-
notype for an FA-B patient is due to mosaicism caused by
the disappearance of the duplication.
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
This study was conducted with the approval of the Institu-
tional Review Board at The Rockefeller University. Written
informed consent was obtained from the legal guardians of the
patient, in accordance with the Declaration of Helsinki. The
Office of Human Subjects Research at the National Institutes
of Health and the Institutional Review Board of the National
Human Genome Research Institute approved the analysis of
the molecular variants, from the cell lines and DNA.
2.2 | Cell culture, DNA and RNA extraction
The lymphoblastoid cell lines (LCL) from the proband and
his mother, established by Epstein–Barr virus (EBV)-trans-
formed B-lymphocytes, were cultured in RPMI (Roswell
Park Memorial Institute 1640) medium (Gibco, Paisley,
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UK), supplemented with 20% fetal bovine serum (FBS)
(Sigma-Aldrich, St. Louis, MO), penicillin–streptomycin
(100 U/ml penicillin G sodium and 100 lg/ml streptomycin
in 0.85% saline) (Gibco), 2.5 lg/ml amphotericin B (Gibco)
and 2 mM L-glutamine (Gibco). The cells were grown in a
fully humidified incubator with 5% CO2 at 37°C. Primary
skin fibroblasts from the proband were grown in Dulbecco
Modified Eagle medium (DMEM, GIBCO) supplemented
with 15% FBS (Sigma-Aldrich, MO) and further supple-
mented and cultured as above. Control LCL (GM 18507)
and Fibroblast (HGADFN168) cell lines were also grown as
described above. Genomic DNA from the lymphoblast and
fibroblast cell cultures was extracted using the DNeasy
Blood and Tissue Kit (Qiagen, Valencia, CA). Total RNA
was extracted using the RNeasy Mini Kit (Qiagen) with an
in-column DNase treatment. Five micrograms of RNA was
then reverse transcribed using the SuperScriptTM IV First-
Strand Synthesis System (Invitrogen, Grand Island, NY).
The cDNA synthesis was performed per the manufacturer’s
protocol. The cDNA was then used as a template for PCR.
2.3 | Diagnostic DEB testing
Initial diagnostic testing for chromosomal breakage induced
by DEB was performed on the proband’s primary
fibroblasts (Fib-2005) and peripheral blood cells (PB-2005)
isolated from the patient in 2005 as described earlier (Auer-
bach, 2015). To follow the progression of mosaicism over
time, chromosomal breakage was again evaluated using a
new blood sample drawn from the patient in 2016 (PB-2016)
and the LCL derived from that blood (LCL-B). The pro-
band’s LCL derived from the PB drawn in 2005 (LCL-A)
was also studied.
2.4 | aCGH
Agilent CGH array was designed to query the entire length
and extended regions of all FA and other inherited bone mar-
row failure syndrome genes. The FANCB (ENSG00000
181544.13; ENST00000398334.5; NM_001018113.2) gene
region on the array extended to 150 kb on either side of the
gene interval. The experimental procedures are as described
previously (Flynn et al., 2014). Briefly, genomic DNA from
the patient and a reference male DNA were differentially
labeled and hybridized to the array.
2.5 | Next-gen sequencing (NGS) and analysis
Targeted capturing and sequencing of the entire length of
FA genes were performed as described previously
(Chandrasekharappa et al., 2013). The number of reads that
mapped to 99 bp intervals across the FANCB gene were tal-
lied with the BedTools command, coverageBed, and plotted
for a randomly selected sample as a control and the samples
with the duplication (proband fibroblast and proband LCL)
in the UCSC genome browser (hg19) with BedGraph tracks.
The precise location of the duplication (chrX:14877976-
14887129 or chrX:14877972-14887133, as there is microho-
mology at the edges of the duplication) was determined
based on a combined manual analysis of the read depth, clus-
tering of soft-clipped reads, and reads with unmapped mate-
pairs. Reads from the FANCB region were re-mapped to an
altered sequence using Novoalign including the inferred
duplication to confirm the breakpoints of the duplication.
2.6 | PCR assay for the FANCB duplication
breakpoint junction in genomic DNA
The gDNA samples were amplified using the KAPA2G Fast
HotStart ReadyMix PCR Kit (KAPA Biosystems Inc.,
Wilmington, MA). The reaction mix and amplification con-
ditions were set-up as per the manufacturer’s instructions.
The sequence for the primers used for the amplification of
the 702 bp FANCB duplication junction product were as fol-
lows- forward primer 50 GGGTTGCTCAAAGGGTACAA
30 (chrX:14886733-14886752) and reverse primer 50
TCAGGGAAAAGGGGGATTT 30(chrX:14878265-14878
283). The FANCB duplication junction primers were
designed such that they face each other across the duplica-
tion junction. We used primers to amplify a 91 bp in the
intron 1 region of FANCB as control. The primer sequences
were- forward 50 CCAAGGATACTTTCTCTTGGTC 30
(chrX:14888971-14888992) and reverse 50 CAGTGTGGT
TCCAGATTATCC 30 (chrX:14888902-14888922). The uni-
versal M13 forward and reverse sequences were added as a
tag to our primer sequence.
2.7 | Sanger sequencing the PCR products
from the FANCB duplication junction PCR in
gDNA
The PCR products were treated with USB ExoSAP-IT
(Affymetrix, Santa Clara, CA) and sequencing reactions
were carried out with the M13 forward (50 tgtaaaacgacg-
gccagt 30) and reverse (50 caggaaacagctatgacc 30) primers,
using the Bigdye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems) and run on ABI3730XL sequencer.
2.8 | Droplet Digital PCR (ddPCR) for
quantitation of FANCB duplication junction in
gDNA
Copy number variance analysis was performed using the
ddPCR system (Bio-Rad, Hercules, CA), adhering to the
MIQE guidelines (Huggett et al., 2013). The primers and
FAM-labeled probe for the FANCB gDNA duplication
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junction were custom designed to target a 185 bp unique
region and are as follows- forward primer sequence 50
ATCTGGGACAATAGGCATCA 30, reverse primer sequence
50 TAGGACCCCTCACCTGTGTA 30 and probe sequence
AAGATAGGGTAGACACCTTAAGAGCTC. The probe
was designed to hybridize to the FANCB exon 3-3 duplica-
tion junction in the gDNA of our samples. The HEX-labeled
fluorescent probe hybridized to an amplicon targeting 60 bp
of intron 22i in the AP3B1 gene, which served as a 2-copy
reference in each cell (AP3B1 ddPCR copy number assay,
UniqueAssayID: dHsaCP2500348, Bio-Rad). The PCR reac-
tion mix was prepared per the manufacturer’s instructions,
with 22 ng gDNA in a total reaction volume of 22 ll, of
which 20 ll was partitioned into 13,000-20,000 water-in-oil
droplets using the Automated Droplet Generator (Bio-Rad).
The optimal primer annealing temperature was determined
by gradient PCR and subsequently, samples were amplified
on the C1000 Touch Thermal Cycler with the optimal
annealing temperature of 58°C (Bio-Rad). After amplifica-
tion, the 96-well PCR plate was placed on the QX200 Dro-
plet Reader (Bio-Rad) and the data were analyzed using the
QuantaSoft analysis software (version 1.7.4). The Quanta-
Soft software was then used to calculate the copy number
variance (CNV) in our sample. CNV is determined by calcu-
lating the ratio of the target (FANCB duplication junction)
molecule concentration to the ratio of the reference (AP3B1)
species concentration multiplied by the number of copies of
the reference species (2 copies of AP3B1) in the genome. In
the absence of the duplication junction in a given droplet, no
PCR amplification of the FANCB exon 3-3 duplication pro-
duct would take place. Only wells with >13,000 droplets
generated were analyzed. The average CNV for each sample
was calculated from nine observations across three experi-
mental replicates.
2.9 | RT-PCR, gel extraction, and cloning of
the full-length FANCB transcript with the
duplication
PCR was performed using cDNA as a template with the
KOD XtremeTM Hot Start DNA Polymerase (EMD Millipore,
Billerica, CA). The forward primer 50 TTGGAGCAGATG
GATACCGT 30 (chrX:14891147-14891166) and reverse pri-
mer 50 AAAGTTTCTACTACAGTAAGCCTCG 30 (chrX:
14861567-14861591) were used to amplify the full-length
FANCB transcript. This generates two products, a wild-type
2952 bp product and a 3973 bp product with the exon 3-3
duplication. The PCR mix was set-up as per the manufac-
turer’s protocol. The larger 3.9 kb product was used as a
template for PacBio sequencing, following gel extraction
and cloning.
The sequence of the FANCB aberrant transcript was
obtained by PacBio sequencing and primers were
subsequently designed to amplify the unique 1009 bp
RT-PCR product from the proband’s fibroblasts using the
forward primer 50 TTGGAGCAGATGGATACCGT 30
(chrX:1489 1147-14891166) and the reverse primer
50TCAAATGCAAATTGATTCCAGT 30 (chrX: 14883667 -
14883688). This represents the coding region of the aberrant
transcript. Following gel extraction and cloning, the 2.9 kb
wild-type and the 1009 bp aberrant FANCB transcripts were
used for viral transduction to generate expression constructs.
The RT-PCR products were excised from the gel and
the DNA was extracted using the PureLink Quick Gel
Extraction Kit (Invitrogen). The extraction was performed
per the manufacturer’s protocol and the resulting DNA was
concentrated by ethanol precipitation. The CloneJet PCR
cloning kit (Thermo Fisher Scientific, Waltham, MA) was
used to clone 250 ng of the concentrated DNA obtained
above, into a positive selection cloning pJET1.2/blunt vec-
tor. The individual colonies obtained were then screened
by PCR for insertion of the correct size product.
2.10 | PacBio Sequencing of full-length
FANCB aberrant transcript
The Pacific Biosciences (Menlo Park, CA) protocol
“Preparing SMRTbell Libraries using PacBio Barcoded
Universal Primers for Multiplex SMRT Sequencing” was
used to create a PacBio sequencing library from the pooled
amplicons using only the library construction portion of the
protocol. The resulting library size and purity was assessed
using a Bioanalyzer (Agilent). Sequencing was performed
on an RS II sequencer (Pacific Biosciences) using P6-C4
sequencing chemistry with 240 min movies. Two SMRT
cells were used to generate over 126,000 polymerase reads.
PacBio raw reads were converted into circular consensus
sequences (CCS) using PacBio SMRTanalysis software
(version 2.3). CCS were analyzed using the PacBio ToFu
pipeline (version 2.2.3) (Gordon et al., 2015), to generate
polished transcript sequences. The transcripts were aligned
to a reference using GMAP (version 2014-12-21) (Wu &
Watanabe, 2005).
2.11 | Droplet Digital PCR for quantitation
of FANCB exon 3-exon 3 junction in cDNA
The cDNA from the proband, mother, and control samples
were used as template to quantify the expression of the
unique FANCB exon 3-exon 3 junction using the Bio-Rad
ddPCR system. The reaction mix was set-up as per the man-
ufacturer’s instructions, and PCR was performed with an
annealing temperature of 54°C. The primer and probe
sequence for the FANCB duplication junction in cDNA were
custom designed and labeled with FAM. The forward primer
sequence is 50 ATTCAGGTGGAGGAAACCT 30, the
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reverse primer sequence is 50 CGTTAGATGACATT
GCTTG 30 and the probe sequence is TGCTTGTGCTG
TATGGAAAGA. The HEX labeled FANCB exon 4-exon 5
primer and probe (UniqueAssayID: qHsaCIP0039596, Bio-
Rad) was used as a reference. The QuantaSoft software was
then used for rare event detection (RED) in our samples.
RED is determined by calculating the ratio of the target
(FANCB duplication junction) molecule concentration to the
ratio of the reference (FANCB control) molecule concentra-
tion in the samples. The ratio was then multiplied by 100 in
order to obtain the percentage of the duplication junction in
our cDNA samples.
2.12 | Viral transduction
For lentiviral transduction experiments, the wild-type and
aberrant FANCB transcripts were transferred from pJET1.2
to pHAGE CMV N-terminus HA-FLAG vector using Gate-
way recombination (Thermo Fisher Scientific). These were
packaged in HEK293T cells using Trans-IT transfection
reagent per the manufacturer’s protocol (Mirus) and were
delivered using lentiviral transduction into proband fibrob-
lasts, FANCB mutant (null) fibroblasts, and BJ foreskin
normal control fibroblasts (ATCC) that were transformed
by the expression of HPV16 E6E7 by retroviral infection.
2.13 | Mitomycin C (MMC) treatment to
assess FANCD2 ubiquitination
Patient fibroblasts, patient LCL, transformed proband
fibroblasts, and FANCB mutant cells were seeded 24 hr
before treatment. The next day, the cells were treated with
1 lM MMC for 24 hr or were left untreated. After 24 hr,
cells were harvested using 0.25% Trypsin-EDTA (Gibco).
2.14 | Western blotting
Whole-cell extracts were prepared by performing cell lysis
using 29 Laemmli sample buffer (Bio-Rad), followed by
sonication and boiling. Samples were separated on 3%–8%
Tris-Acetate or 4%–12% Bis-Tris gradient gels (Invitrogen)
by SDS-PAGE. Membranes were blocked with 5% skim milk
in 0.1% Tween 20/TBS (TBST) for 1 hr. Immunoblot was
performed using primary antibodies against FANCD2 (Novus
NB100-182), HA.11 (BioLegend 16B12) and a-Tubulin
(Sigma DMA1). Membranes were incubated with primary
antibodies at room temperature for 2 hr then washed three
times with TBST. Membranes were incubated with anti-rabbit
or anti-mouse HRP-linked secondary antibodies at room tem-
perature for 1 hr and washed three times with TBST. Mem-
branes were developed using Western Lightning Plus-ECL
(PerkinElmer) and images were obtained by chemilumines-
cence on ImageQuant LAS4000 (General Electric).
2.15 | Immunofluorescence for FANCD2 foci
formation
Cells were seeded onto cover slides in 6-well culture dishes.
The next day, cells were treated with 1 lM MMC for 24 hr
or were left untreated, after which cells were fixed with 3.7%
formaldehyde and permeabilized with 0.5% Triton in PBS.
Cells were blocked in 5% FBS in PBS (w/v) for 1 hr at room
temperature, incubated with anti-rabbit FANCD2 antibody
(Novus NB100-182) overnight at 4°C, and washed three
times with 5% FBS in PBS. Cells were then incubated with
Alexa 488 goat anti-rabbit IgG (H + L) (Invitrogen
#A32731) for 1 hr at room temperature, washed three times
in 5% FBS in PBS, then coverslips were mounted using
DAPI Fluoromount-G (SouthernBiotech).
3 | RESULTS
3.1 | Clinical presentation
The patient presented at 19 months of age with failure-to-
thrive. The birth weight was 3.12 kg and he was at the
50th percentile for height and weight at 6 months of age,
but at presentation his height was at the 5-10th percentile
and his weight was below the 5th percentile. He was
referred to Gastroenterology and Hematology for evaluation
and the possibility of the diagnosis of an inherited bone
marrow failure syndrome. He had no symptoms of diarrhea
and no previous history of infections but had delay in
speech development. The physical exam was normal except
for several hyperpigmented areas on the abdomen and the
axilla, and hypopigmented areas on the back and legs.
Sweat testing was negative. Initial blood counts revealed
mild neutropenia (Table 1). The bone marrow biopsy
showed a few areas with 50-70% cellularity, formed mainly
by erythroid cells; normal myeloid maturation; and ade-
quate number of megakaryocytes. Cytogenetics and FISH
were normal.
The patient is presently 13 years of age and is at the
16th percentile for height and less than the 5th percentile
for weight. He has mild neutropenia and thrombocytopenia
TABLE 1 Hematological manifestations in the proband
Patient Age
19 months 9 years 13 years
Blood Count
WBC (K/ll) 5.36 3.7 3.6
ANC (cells/ll) 1288 1500 1000
Hb (g/dl) 12.2 13.5 12.9
MCV (fl) 82.6 86.3 90.2
Platelets (K/lL) 258 155 140
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and continues to be borderline macrocytic. The bone mar-
row aspirate and biopsy at age 13 showed hypocellular
marrow (20%) with trilineage hematopoiesis with matura-
tion, focal areas of erythroid predominance and decreased
megakaryocytes; no dysplasia; and, markedly decreased to
absent iron stores. Cytogenetics and FISH were normal. He
has no significant health issues at this time.
3.2 | DEB test and complementation analysis
reveal diagnosis of FA-B group with revertant
mosaicism
Clinical DEB breakage test using proband’s dermal fibrob-
lasts (Fib-2005; RA2977) was consistent with Fanconi ane-
mia (Figure 1, Table S1), albeit a high dose of DEB (0.1 lg/
ml) was necessary to elicit breakage levels seen in typical
FA patients. Peripheral blood at the time of diagnosis (PB-
2005; B05-0428.1) exhibited elevated chromosomal break-
age. However, only thirty percent of cells analyzed at that
time showed breaks, consistent with revertant mosaicism in
the patient cells. The presence of mosaicism was confirmed
in samples collected later from the patient, including the
peripheral blood from 2016 (PB-2016) which had an average
of 0.01 breaks per metaphase and the LCL derived from this
PB (LCL-B), which showed an average of 0.28 breaks per
metaphase (Figure 1b). In addition, the LCL cell line estab-
lished from PB collected at diagnosis in 2005 (LCL-A),
showed an average of 0.82 metaphases with breaks when
tested in 2017. Taken together, the breakage studies on dif-
ferent samples from the patient, suggested presence of an
unstable mutant allele that was being reverted both during
in vivo and in vitro growth. Complementation tests
FIGURE 1 Results of chromosome
breakage with and without DEB.
(a) Results of clinical testing. Proband
fibroblasts (Fib-2005) and PB-2005 were
tested as part of the original diagnosis in
the year 2005. (b) Results of research
testing performed in 2017 on the proband’s
LCL from 2005 (LCL-A) and 2016 (LCL-
B), as well as the proband’s peripheral
blood drawn in 2016 (PB-2016). The
FANCAmut LCL represents the typical DEB
test results from the LCL of a patient with
FA and the mother’s LCL (LCL-2016) was
included as a healthy control. The details of
the breakage test results are shown in
Table S1. Asterisks indicated that the test
was done on a separate date even though it
is shown on the same graph
FIGURE 2 Detection and sequencing of duplication breakpoint. (a) ArrayCGH of DNA from proband’s fibroblasts. Differential hybridization
data obtained from the hybridization of genomic DNA from proband fibroblasts against a male reference DNA on a custom designed CGH array.
The Log2 ratio of the signal intensity from test versus reference DNA is shown on the y-axis, and X- axis shows the entire FANCB gene region.
Increased signal intensity from proband DNA (expanded at the bottom), around exon 3 indicates duplication of this ~10 kb region in FANCB
(NM_001018113.2). (b) Targeted capture and next-gen sequencing (NGS) of the FANCB gene region. Targeted capture/sequencing of genomic
DNA shows increased number of reads for the duplicated region (chrX:14877976-14887129 or chrX:14877972-14887133) in the proband fibroblast
and LCL-A-2005, compared to a control DNA (top 3 tracks). The ratio of depth of coverage (bottom 3 tracks) confirms the duplicated region.
Discordant reads at the region of duplication showed a tandem intragenic duplication of 9154 bp in FANCB, head to tail, in the same orientation and
is expanded at the bottom of the hg tracks for FANCB. The red rectangular boxes indicate a shared homology of four bases (GTAG) at both ends of
the breakpoint region, but only one in the duplicated region. (c) Sequence alignment of the FANCB duplication junction. The sequence alignment of
the breakpoint junction, along with the sequence of the exon 2 and intron 3, the two ends of the duplication are shown here. The sequence at the
junction suggested a microhomology-mediated duplication event leading to the disease
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Exon 2       CAGCTTCATCAGTAAAGAAGATAGGGTAGgtaaatcaaaggtctggcttgtact
Intron 3                   actgtcaggtaaccagacagtactaGTAGACACCTTAAGAGCTCTTAATGGAAA
Duplication Junction CAGCTTCATCAGTAAAGAAGATAGGGTAGACACCTTAAGAGCTCTTAATGGAAA
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performed using the patient fibroblasts showed correction of
the cellular sensitivity to crosslinking agents by the expres-
sion of FANCB.
3.3 | Molecular diagnosis reveals that the
patient carries an intragenic duplication in the
FANCB gene
Conventional Sanger sequencing of the coding region and
NGS of the entire FANCB gene did not reveal any
pathogenic sequence variants. However, aCGH designed to
query the entire length of all FA genes showed an increased
signal indicating a duplication of an intragenic region of
FANCB in DNA from the patient’s fibroblasts (Figure 2a).
The NGS data showed a clear increase in the number of
sequence reads for the same intragenic FANCB region. The
sequence reads crossing the breakpoint provided the precise
boundaries of the duplication and revealed a tandem intra-
genic duplication of 9154 bp in FANCB (Figure 2b). The
duplicated region (chrX:14877976-14887129 or 14877980-
FIGURE 3 Evaluation of gDNA by PCR to show the presence of the unique duplication junction in the proband and the mother. (a) PCR of
FANCB duplication junction. DNA samples from the patient, mother, father, and control were tested for the presence of the breakpoint junction.
Presence of the duplication in the mother’s as well as the proband’s DNA was observed. The top panel represents the 702 bp PCR product of the
FANCB duplicated region. The bottom panel represents a 91 bp PCR product from the FANCB intron 1 (control) amplification. Fib refers to
Fibroblast DNA and PB refers to peripheral blood DNA. LCL-A was established from the patient’s PB-2005, and DNA was collected from the
LCL at that time (LCL-A-2005). This cell line was subsequently grown at different times in 2015 and 2017. LCL-B was established from the
patient’s PB-2016, and DNA was collected at that time (LCL-B-2016). This cell line was grown again in 2017 and DNA was collected (LCL-B-
2017). (b) Copy Number Variance Analysis of FANCB duplication in gDNA using ddPCR. Standard errors are barely visible as they do not
exceed 0.63%; n = 9 observations per sample. The copy number variance was evaluated by performing ddPCR with probes specific for the
FANCB genomic DNA duplication junction region, and a two-copy reference gene. The variability in the extent of duplication in DNA from
proband supports mosaicism. The extent of duplication in DNA from mother is <50% indicating mosaicism in her DNA as well
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14887133) extended from within the alternatively spliced,
noncoding exon 2, the entire exon 3, and nearly 90% of
intron 3. A shared homology of four bases GTAG (CTAC in
the coding strand) at both ends of the breakpoint region
(chrX:14877972-14877976 at the proximal end and
chrX:14887129-14887133 at the distal end), but only one in
the duplicated region, suggested a microhomology-mediated
duplication event leading to the disease (Figure 2b,c).
3.4 | Quantitation of the FANCB duplication
in genomic DNA reveals variable extent of
duplication
A PCR assay was designed to amplify the breakpoint junc-
tion in the gDNA. The presence of the junction and thus
the duplication was apparent in DNA from the proband
and mother, and as expected for a X-linked disease, not in
the DNA from father (Figure 3a). A ddPCR assay was
developed to quantitate the extent of duplication in the
DNA samples. The number of copies of the duplication
junction relative to a 2-copy control from an unrelated
position in the gDNA was quantitated for the patient LCL,
fibroblast and PB samples, as well as the mother’s LCL
and PB samples (Figure 3b). The DNA from the proband’s
fibroblasts had 92% duplication. The PB-2005 DNA
showed 93% duplication, whereas the LCL derived from
this PB (LCL-A) showed a decrease in the extent of dupli-
cation at three different time points over several years, with
79%, 5.1%, and 0% duplication in DNA extracted from
cells grown in 2005, 2015, and 2017, respectively. The PB
DNA collected eleven years later (PB-2016), displayed
7.9% duplication, whereas the LCL generated from this PB
(LCL-B), displayed 2.9% and 0.05% duplication in DNA
extracted from cells in 2016 and 2017, respectively.
We also quantitated the duplication in two PB DNA
samples from the mother. PB-2005 showed 25% duplica-
tion, whereas PB-2016 and the LCL established from it
(LCL-2016) both showed 21% duplication. The observed
duplication frequency in the mother’s DNA was much less
than the 50% anticipated for a heterozygous carrier, indica-
tive of revertant mosaicism in the hematopoietic cells of
the mother as well (Figure 3b).
3.5 | The intragenic duplication results in a
longer, aberrant FANCB transcript
We evaluated the consequence of the intragenic duplication
on the FANCB transcript by RT-PCR with primers amplify-
ing the full-length cDNA FANCB template (Figure 4a).
The RNA from the proband LCL-A-2005 and fibroblasts
(Fib-2005) showed the presence of the full-length wild-type
2.9 kb product, as well as a 3.9 kb product that contains
the duplication. Cloning and PacBio sequencing of the
aberrant larger transcript revealed duplication of exon 3
(Figure 4b) and a unique exon 3-exon 3 duplication junc-
tion sequence in the transcript (Figure 4c). The duplication
of exon 3 results in generating a stop codon right near the
junction, and if expressed, encodes a truncated protein
p.A319*, much shorter than the full-length protein of 859
amino acids.
3.6 | The aberrant FANCB transcript level
correlates with the level of genomic DNA
duplication
We quantified the percentage of the transcript with the
duplication compared to the wild-type FANCB transcript
using a probe specific for the duplication junction sequence
(exon 3-exon 3) and another probe specific for a FANCB
wild-type (exon 4-exon 5) sequence (Figure 4d). We
observed nearly 82% duplicated transcript in the proband
fibroblast, whereas the proband LCL-A-2005, LCL-A-
2015, and LCL-B-2016 samples displayed 66.6%, 4.6%,
and 2.5% duplicated transcript, respectively. The mother’s
LCL exhibited a 25.6% duplicated message. The expression
levels of the duplication in the FANCB transcript appears
to be consistent with the CNV observed in the gDNA in
these cells. Therefore, normal splicing of the duplicated
transcript resulting in a wild-type mRNA, if occurring, is
minimal. Since the LCL-A-2017 and LCL-B-2017 genomic
DNAs showed almost no duplication, we did not quantify
the duplicated transcript in these samples by ddPCR.
3.7 | FANCD2 ubiquitination is defective in
the proband fibroblasts, but is regained in the
proband LCL
Proband fibroblasts showed the absence of FANCD2 ubiq-
uitination either with or without MMC treatment, confirm-
ing the defective FA pathway function upstream of
FANCD2 ubiquitination in this patient (Figure 5a–c).
FANCD2 foci formation assay also showed the absence of
detectable MMC-induced FANCD2 foci (Figure 5d,e). On
the other hand, both LCL-A-2017 and LCL-B-2017
showed ubiquitination of FANCD2 that was enhanced with
MMC treatment (Figure 5c). This finding suggests that
majority of these LCLs grown in 2017 were derived from
revertant cells that have restored the intact FA pathway
allowing ubiquitination of FANCD2 upon DNA damage.
3.8 | Functional evaluation of the mutant
FANCB cDNA reveals absence of FANCD2
ubiquitination
Complementation of HPV16 E6E7-transformed proband
fibroblasts with FANCB WT cDNA restored FANCD2
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ubiquitination, whereas the expression of the mutant cDNA
(FANCB p.A319*, predicted to be 37kD) failed to comple-
ment FANCD2 ubiquitination upon MMC treatment
(Figure 6). The expression of pA319* allele was lower
than the WT suggesting that this allele was unstable. Simi-
lar complementation results were observed in an
FIGURE 4 Evaluation of the consequence of duplication on the FANCB transcript. (a) RT-PCR product of full-length FANCB
(NM_001018113.2) transcript in the proband, mother and control cells. The primers amplified a 2.9 kb FANCB transcript and a larger (3.9 kb)
transcript with the duplication. Proband’s cells, particularly the LCL-A-2005 and Fib-2005, showed a larger transcript in addition to the WT
transcript. (b) PacBio sequencing of the larger transcript. The sequences from the larger transcript, aligned to the reference genome modified to
accommodate exon 3 duplication, indicate the duplicated exon 3 is now part of the aberrant transcript. (c) Diagram showing the unique FANCB
exon 3-exon 3 duplication junction. RT-PCR and sequencing of the exon 3-exon 3 junction region in the transcript with the duplication reveals a
stop codon at the beginning of the junction. Primers (red and green arrows) were designed to amplify a unique 187 bp junction product from
cDNA template. The transcript sequence predicts translation termination in close proximity to the junction. (d) The RNA from fibroblasts and
LCL were evaluated by RT-PCR followed by ddPCR quantitation, with probes specific for the aberrant FANCB message (probe for the exon 3-
exon 3 duplication junction region), and WT FANCB transcript (probe for the exon 4-exon 5 junction). The percentage of aberrant transcript
compared to the total FANCB transcript is presented. Vertical bars represent the standard error of the measurements; n = 3 separate observations
performed in triplicate (total of nine data points) for each sample
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independent FANCB mutant (null) fibroblast cell line (Fig-
ure 6). We were unable to visualize the endogenous
FANCB protein with the available antibodies even in the
WT cells.
4 | DISCUSSION
We describe here an FA patient assigned to the FA-B group
based on complementation tests performed on cultured skin
fibroblasts. A disease-causing intragenic duplication in
FANCB was discovered by aCGH. Next-gen targeted captur-
ing and sequencing of the entire FANCB gene revealed the
precise region of duplication. This was possible due to the
high depth (~5009), complete coverage of the gene
sequence in our design. The sequence reads spanning the
duplication breakpoints provided the junction sequences and
indicated a tandem duplication. The sequence at both ends
of the duplication fragment carried a 4 bp microhomology
region and the breakpoint junction retained one of these
repeats. A homology of 2-100 bp with no insertions or
deletions at the breakpoint defines alternative end-joining
(alt-EJ) (Yang et al., 2013) as a mechanism that led to the
intragenic duplication. In a genome-wide CNV analysis, it
was observed that two-thirds of genomic duplications share
a short microhomology between the two ends of the duplica-
tion, and most interstitial duplications are tandem and lie in
direct orientation (Newman, Hermetz, Weckselblatt, &
Rudd, 2015), similar to the duplication in our FA-B patient.
FA-B group patients are male and either have a de novo
mutation or inherit a pathogenic variant allele from a
heterozygous carrier mother, as seen in our patient. Interest-
ingly, the variant allele in the mother’s PB and LCL cells
was present at a lower level (21%–25%) than the 50%
expected of a typical heterozygous carrier, indicating that
reversions occurred even in the carrier mother. Another pos-
sibility is that the duplication occurred de novo in the
mother. However, given the instability of the duplication
even in the proband’s fibroblasts, we favor the reversion as a
source of the mosaicism in the mother. Our finding raises a
possibility that some of the FANCB mutations ascribed to be
of de novo origin in other patients may actually be present in
the mother but may be mosaic in her blood. Such low-level
mosaicism may not be detected by standard testing, and thus
sensitive methods should be employed to detect the variant
in the carrier, prior to declaring a patient harboring a de novo
variant.
The presence of mosaicism in fibroblasts (8% wild-
type allele) is unprecedented and indicative of the very
unstable nature of the identified duplication. Although this
FIGURE 6 Functional evaluation of FANCB WT and mutant cDNA. Proband fibroblasts, FANCB mutant (null) fibroblasts and BJ control
fibroblasts were HPV16 E6E7 transformed. Either empty vector, wild-type FANCB cDNA, or mutant FANCB cDNA (p.A319*) was introduced
into proband fibroblasts and FANCB mutant (null) fibroblasts. After puromycin selection, cells were cultured with or without MMC 1 lM for
24 hr, after which cells were harvested for the FANCD2 and HA western blot assays
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low-level mosaicism did not lead to a detectable FANCD2
ubiquitination in the primary fibroblasts, transformation of
fibroblasts by HPV16 E6E7 made this mosaicism more
detectable, as shown by the presence of FANCD2 ubiquiti-
nation and foci formation upon MMC exposure, presumably
due to an increased selective advantage of cells with active
FA pathway. We observed a 20% reversal to wild-type in the
proband LCL-A cells grown in 2005, whereas both LCL-A
and LCL-B cells grown in 2017 showed nearly 100% rever-
sal to wild-type. The LCLs show that the reversal is occur-
ring in vitro; however, we also observed the reversal
occurring in vivo, with a 90% reversal to WT in PB between
2005 and 2016. We have previously described mosaicism in
an FA patient carrying an intragenic duplication of a similar
length, in the FANCT/UBE2T (Rickman et al., 2015). That
patient had variable levels of duplication in the PB cells in
the UBE2T gene on chromosome 1. The duplication and the
associated reversal were mediated by Alu repeats present at
the ends of the duplication with nearly 90% identity in their
sequences. The X-linked FANCB mosaicism in our patient is
interesting in that the flanking sequences share a homology
of only four bases, and the reversion of the duplicated allele
to WT allele may also be caused by the same microhomol-
ogy-mediated mechanism that led to the initial duplication.
Unlike typical X-linked FA-B patients, who usually pre-
sent with severe developmental abnormalities, overlapping
with the phenotype of the VACTERL syndrome with
hydrocephalus, the congenital abnormalities displayed by
this patient were much milder. We speculate that this could
be due to the reversal of the duplication resulting in a
wild-type, functional allele in a fraction of the patient cells
during fetal development. The consequence of mosaicism
is apparent as the expression of WT and mutant transcripts
in the RNA are proportional to the extent of duplication in
the genomic DNA, suggesting there is no degradation of
the aberrant transcript by nonsense-mediated decay. How-
ever, the functional evaluation of the mutant FANCB
cDNA (p.A319*) resulted in no FANCD2 ubiquitination,
indicating that the truncated protein does not restore normal
FA pathway function. FANCB, along with FANCL and
FAAP100, is absolutely required for monoubiquitination of
the FANCD2/FANCI complex (Huang et al., 2014; Rajen-
dra et al., 2014), a key step that results in the recognition
and initiation of DNA damage repair caused by DNA
crosslinks. FANCB knockout mice demonstrate impairment
of hematopoietic stem cell function (Du et al., 2015), one
of the hallmarks of FA. Thus, molecular characterization of
FANCB mutations and their influence on the phenotypic
presentation of the patients harboring them, is critical for
understanding the pathogenesis in FA.
Unlike sequence variants, duplications are difficult to
identify by sequencing and may be missed. The conse-
quences of the duplications are difficult to assess as well,
unless the breakpoints are sequenced. Targeted sequencing
strategies focusing only on exonic regions might not be able
to provide the precise breakpoints. Conventional means of
sequencing DNA and cDNA from the patient did not reveal
the disease-causing variant. This is particularly challenging
when the duplication is in a mosaic form, present in only a
subset of the patient cells (Biesecker & Spinner, 2013). We
identified an intragenic duplication in an FA patient from an
X-linked FA-B group by aCGH, determined the precise loca-
tion of the duplication by deep sequencing, using NGS of
genomic DNA, and evaluated its consequence on the tran-
script by PacBio sequencing. PacBio sequencing allowed
sequencing larger molecules such as the 3.9 kb FANCB
aberrant message at a higher depth, nearly 50,000 full-length
reads. This allows for detection of minute fractions of alter-
natively spliced products. We evaluated the biological conse-
quence of the duplication by detailed analysis of DNA and
RNA. We could detect traces of duplication even in the LCL
that carried only 3% of the duplication. Thus, sensitive and
versatile technologies are important to ensure proper molecu-
lar diagnosis in FA patients.
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